|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Silencing of Bcl-2 increased apoptosis in AM-1 cells in vitro and inhibited tumor nodule formation of AM-1 cells in vivo.
|
30801855 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, we tested its ability to discriminate follicular lymphomas by the tumour grade and the BCL2 protein expression.
|
30609603 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, BCL-2 attenuated the tumor inhibiting effect of miRNA-448.
|
30316787 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Together, our data indicate that protection by hnRNP L overrides the presence of multiple 3'UTR introns, allowing these aberrant mRNAs to evade NMD and promoting BCL2 overexpression and neoplasia.
|
30530525 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, the combination therapy significantly suppressed tumour volume and prolonged the life span of mice (P < 0.05) by upregulating the expression of Bcl-2/Bax and Caspase-3 and by downregulating the TLR4/NF-κB signalling, the expression of p-AKT/AKT and the production of proinflammatory factors.
|
30448904 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The 2016 revised World Health Organization (WHO) classification of lymphoid neoplasms included the category of high-grade B cell lymphomas (HGBLs) with combined MYC and BCL2 and/or BCL6 rearrangements (double-hit, DH).
|
30613837 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BCL2A1 is an anti-apoptotic member of the BCL-2 family that contributes to chemoresistance in a subset of tumors.
|
30042493 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of miR-34a acts as a tumor suppressor by transcriptional regulating one of the signaling pathways (TP53), NOTCH, and transforming growth factor beta (TGF-β), Bcl- 2 and SIRT1genes, HDAC1 and HDAC7, Fra-1, TPD52, TLR Via CXCL10.
|
31244419 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Unraveling Tumor Heterogeneity in an Apparently Monolithic Disease: BCL2 and Other Players in the Genetic Landscape of Nodal Follicular Lymphoma.
|
30931307 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant over-expression was observed in Bax, Casp3, and Trp53 and downregulated in Bcl2 mRNA level in tumor tissue after treatment with scorpion venom (p < 0.05).
|
30617443 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies have emphasized a key role for the anti-apoptotic Bcl-2 family member Mcl-1 in conferring tumor cell survival and drug resistance in breast cancer (BC).
|
30374681 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RRx-001 is demonstrated to induce Nrf2 in normal tissues, mediating protection, and to downregulate the Nrf2-controlled antiapoptotic target gene, B-cell lymphoma 2 (Bcl-2) in tumors, mediating cytotoxicity.
|
31250159 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among all Bcl-2 antiapoptotic members, Mcl-1 expression (but not Bcl-2 or Bcl-xL) was found to be upregulated in both chemoresistant OSCC lines and chemoresistant tumors when compared with their respective sensitive counterparts.
|
30395230 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, multinomial linear regression showed higher possibility for association between high expression of Ki-67, low expression of p53 and high expression of BCL-2 with age, grade, stage and tumor (T) stage.
|
31289309 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We have defined a clinically and biologically distinct subgroup of tumors within GCB-DLBCL characterized by a gene expression signature of HGBL-DH/TH- BCL2.
|
30523716 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of <i>VAPA-Rab31</i> upregulated anti-apoptotic protein Bcl-2 and phosphorylated CREB both in cells and xenograft tumors.
|
31083279 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The antiapoptotic Bcl-2 proteins are significantly altered in several tumor types which position them as striking targets for therapeutic intervention.
|
30965082 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>96</b> inhibited xenografts growth by reducing the expression of TNF-α and Bcl-2 in the tumour tissue.
|
31288582 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Notably, both PDXs that were highly responsive to the combination therapy expressed low HER2 protein levels and lacked <i>ERBB2</i> amplification, suggesting that BCL-2/X<sub>L</sub> inhibition can enhance sensitivity of tumors with low HER2 expression.
|
30962322 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The present study also revealed that lncRNA‑MEG3 transfection suppressed tumor growth mainly by decreasing the expression of vascular endothelial growth factor and increasing the expression of Bcl‑2 in vivo.
|
31524253 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mouse lymphoma tissues were extracted, and the expressions of MMP-9 and Bcl-2 messenger ribonucleic acids (mRNAs) in the xenograft tumor were detected using Real-time polymerase chain reaction (PCR).
|
30779087 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, Inotodiol notably induced tumor cell apoptosis by Annexin-V-FITC apoptosis assay, which is associated with activation pro-apoptotic proteins of PARP, cleaved caspase-3 and Bax expression, inhibition anti-apoptotic protein Bcl-2 expression.
|
31128995 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with the BCL2 inhibitor Navitoclax lead to a reduction of growth of SCNPC PDX tumors <i>in vivo</i>, while ARPC PDX models were more resistant.
|
31806643 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Connexin 43 (Cx43) protein and its cell-communication channels have been assigned tumor suppressor functions while the anti-apoptotic Bcl-2 (B-cell lymphoma-2) protein has been associated with negative prognostic significance in cancer.
|
31766723 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The B-cell lymphoma 2 (Bcl-2) gene encodes for an antiapoptotic protein associated with the onset of many human tumors.
|
30620563 |
2019 |